475272-62-9

Usage

Uses

Used in Pharmaceutical Industry:
2-Pyridinecarboxylic acid, 6-methoxy-5-nitro-(9CI) is used as a pharmaceutical compound for its potential medicinal properties. Its anti-inflammatory and anti-bacterial effects make it a promising candidate for the development of new drugs to treat various diseases and conditions.
Further research is necessary to fully understand and harness the therapeutic applications of 2-Pyridinecarboxylic acid, 6-methoxy-5-nitro-(9CI). Its structural and functional properties contribute to its potential as a valuable component in drug discovery and development processes.

Upstream product

• 16013-85-7 2,6-dicholoro-3-nitropyridine 
• 67-56-1 methanol 
• 353277-27-7 6-chloro-5-nitropyridine-2-carboxylic acid 
• 124-41-4 sodium methylate 
• 39745-39-6 6-methyl-3-nitropyridin-2-one 
• 74-88-4 methyl iodide 
• 92138-35-7 6-chloro-3-nitro-1H-pyridin-2-one 
• 40851-91-0 6-chloro-2-methoxy-3-nitropyridine 

Downstream Products

• 475272-68-5 methyl 5-amino-6-methoxypyridine-2-carboxylate 

Relevant academic research and scientific papers

2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY

A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful in therapy, e.g. for the treatment of cancers, inflammation, autoimmune diseases and graft-versus host diseases (e.g. in transplantation patients). A pharmaceutical composition comprising the compound or its salt and a method for preparing the compound.

NOVEL ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS

The present invention relates to a chemical compound according to general formula (1).

Design and application of an α-helix-mimetic scaffold based on an oligoamide-foldamer strategy: Antagonism of the Bak BH3/Bcl-xL complex

The prevention of cell death by the antiapoptotic protein Bcl-xL has been linked to a number of cancers. Bcl-xl binds to the BH3 domain of the proapoptotic protein Bak, thus preventing programmed cell death. A competitive assay and docking studies have shown that the polyamide scaffold 1, which was synthesized based on a rational structure-based design, interferes with the Bak BH3/Bcl-xl complexation.

Proteomimetic compounds and methods

The present invention relates to compounds and pharmaceutical compositions which are proteomimetic and to methods for inhibiting the interaction of an alpha-helical protein with another protein or binding site. Methods for treating diseases or conditions which are modulated through interactions between alpha helical proteins and their binding sites are other aspects of the invention.